List view / Grid view
12 January 2016 | By Victoria White
The NDA for venetoclax is for the treatment of people with chronic lymphocytic leukaemia who have received at least one prior therapy, including those with 17p deletion...
11 January 2016 | By Victoria White
AbbVie's investigational HCV regimen, combining ABT-493 and ABT-530, will be evaluated in patients with genotypes 1-6 chronic HCV infection...
7 December 2015 | By Victoria White
Janssen-Cilag International NV has announced data from the Phase 3 RESONATE-2 (PCYC-1115) trial that show ibrutinib (Imbruvica) was superior to chlorambucil in all efficacy endpoints measured in patients with treatment-naïve chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) aged 65 or older.
1 December 2015 | By Victoria White
Empliciti (elotuzumab) has been approved as combination therapy with Revlimid (lenalidomide) and dexamethasone (ERd) in patients who have received one to three prior therapies.
16 November 2015 | By Victoria White
The data show high rates of sustained virologic response at 12 weeks post-treatment in non-cirrhotic patients with chronic hepatitis C virus infection...
16 November 2015 | By Victoria White
Results announced show that 95% of patients achieved a sustained virologic response at 12 weeks post-treatment...
13 November 2015 | By Victoria White
AbbVie has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for labelling considerations based on safety and efficacy results from the Phase III HELIOS trial investigating the use of Imbruvica (ibrutinib) plus bendamustine and rituximab (BR) versus placebo plus BR in relapsed or…
19 October 2015 | By Victoria White
Viekirax and Exviera are the first treatments for chronic HCV to combine three direct-acting antiviral agents to target the infection at multiple steps in the viral lifecycle...
28 September 2015 | By Victoria White
The approval provides a new interferon and ribavirin-free treatment option for patients with most common type of hepatitis in Japan...
The US Food and Drug Administration (FDA) has approved AbbVie’s Humira (adalimumab) for the treatment of moderate to severe hidradenitis suppurativa.
11 September 2015 | By Victoria White
Interim results from the independent AMBER study demonstrated a 98% SVR12 rate in patients who completed a 12- or 24-week treatment regimen...
2 September 2015 | By Victoria White
The FDA has accepted for priority review the BLA for Empliciti (elotuzumab) for the treatment of multiple myeloma as combination therapy...
27 July 2015 | By Victoria White
The EMA validated for review the Marketing Authorisation Application (MAA) for Empliciti for the treatment of multiple myeloma...
27 July 2015 | By Victoria White
The US FDA has approved AbbVie’s Technivie in combination with ribavirin for the treatment of adults with genotype 4 chronic hepatitis C virus infection...
20 July 2015 | By Victoria White
The US FDA has granted C2N-8E12 (ABBV-8E12) an orphan drug designation for the treatment of progressive supranuclear palsy (PSP)...
